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ABSTRACT
Background: It has been reported that measurements of eosinophil-derived neurotoxin (EDN) may be useful
for identifying eosinophil activities in allergic diseases including atopic dermatitis.
Methods: EDN concentrations in the urine were measured by enzyme-linked immunosorbent assay, and the
number of eosinophils in the peripheral blood was counted in 30 patients with atopic dermatitis. The severity of
atopic dermatitis was graded on the criteria proposed by Rajka and Langeland. The disease activity was as-
sessed by each patient on a visual analogue scale (VAS).
Results: Urinary concentrations of EDN in patients with atopic dermatitis showed a significant positive correla-
tion with disease severity. Urine EDN concentrations also correlated with VAS scores for itching, skin condition,
overall skin symptoms and total VAS score, but not with the VAS score for skin dryness. Urinary EDN concen-
trations did not correlate with the number of eosinophils in the peripheral blood.
Conclusions: The urinary EDN concentration in patients with atopic dermatitis is a useful clinical marker for
monitoring disease activity.
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INTRODUCTION
Eosinophils are important effector cells in allergic dis-
eases. It is therefore arguable that proper disease
monitoring should include an evaluation of the de-
gree of eosinophilic inflammation1 in addition to
symptom recordings and function measurements.
One of the most extensively investigated specific
markers of eosinophils has been the serum level of
eosinophil cationic protein (ECP), but the clinical
usefulness of serum ECP levels has been questioned
because of problems in sample processing and the
great variability of measured values.2 Eosinophil-
derived neurotoxin (EDN), also called eosinophil pro-
tein X (EPX), is the basic eosinophil granule protein
that can be accurately measured only in urine,3 and it
has been suggested that urinary EDN may be a valid
alternative to measurements of eosinophil proteins in
serum.4
We reported an efficient enzyme-linked immuno-
sorbent assay (ELISA) method for measuring specifi-
cally human blood and urinary EDN.5 In addition, we
showed that the method may be useful for identifying
the possible roles of eosinophils in ongoing asthma6
and allergic diseases.7 We have expanded these stud-
ies and, in this paper, demonstrated that the urinary
concentration of EDN in patients with atopic dermati-
tis is a useful clinical marker for monitoring disease
activity.
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Fig. 1 Significant relationships between urinary EDN con
centrations and the disease severity in patients with atopic 
dermatitis. The corelation between urinary EDN concentra
tions and severity score was r＝0.465, p＜0.01.
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Fig. 2 Significant relationships between urinary EDN con
centrations and VAS score for itching in patients with atopic 
dermatitis. The corelation between urinary EDN concentra
tions and the VAS score was r＝0.601, p＜0.001.
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METHODS
SUBJECTS
Thirty patients with atopic dermatitis (18 males and
12 females), median age 29.2 years with ages ranging
from 16 to 35 years, underwent an examination at
Shin-Ohra Hospital, Gunma Institute for Allergy and
Asthma, between August and December, 2005. The
diagnosis of atopic dermatitis was made according to
the clinical and morphological criteria defined by
Hanifin and Rajka.8 The severity of atopic dermatitis
was graded according to the criteria proposed by Ra-
jka and Langeland.9 All subjects were on their first
visit to our hospital, and had been treated with topical
corticosteroids, anti-allergic agents, antihistamines,
and so on. Each patient assessed the grade of nine
items (general physical condition, fatigue, mental
stress, sleep, excessive eating or drinking, excessive
work or study, and the dermatological signs itching,
skin dryness and skin condition) on a 10-cm visual
analogue scale (VAS). Samples of blood and urine
were obtained from the patients.
The Institutional Ethics Committee of Gunma Insti-
tute for Allergy and Asthma at Shin-Ohra Hospital ap-
proved the study, and written informed consent was
obtained from each individual before the study com-
menced.
URINE SAMPLING PROCEDURES
Because of the reports showing circadian variations
in urinary EDN,10-12 samples of blood and urine were
obtained in the morning (9.00 to 11.00). Urine was
collected from each individual as a spot sample. After
30 minutes of collection, urine samples were centri-
fuged at 1350×g for 10 minutes at 4℃, and then
transferred to new plastic tubes. Each sample was ali-
quoted into a new plastic tube and stored at −20℃ un-
til the assay below.
SANDWICH ELISA FOR EDN
We developed an efficient ELISA method for EDN,5
which has already been introduced to the market by
Medical and Biological Laboratories Co., Ltd., Na-
goya, Japan. All assays were performed in duplicate
for each sample, and the mean values were reported.
The concentrations of urinary creatinine (Cr) were
determined with an L-type creatinine-F assay system
(Wako Pure Chemical, Osaka, Japan). Urinary EDN
concentrations were expressed as μg per millimole of
Cr (μgmmol Cr) to correct them for urine volume.
COUNTING THE NUMBER OF EOSINOPHILS
The eosinophils in the peripheral blood were counted
automatically by the Beckman Coulter counter
(Beckman Coulter, Fullerton, CA, USA) and the
MAXM AL system (Beckman Coulter).
STATISTICAL ANALYSIS
Correlation coefficients were obtained using the
Spearman’s rank correlation procedure. Probabilities
less than 5% were considered statistically significant.
RESULTS
RELATIONSHIP BETWEEN URINARY EDN CON-
CENTRATION IN ATOPIC DERMATITIS AND DIS-
EASE SEVERITY
EDN concentrations in urine from patients with
atopic dermatitis correlated significantly with the dis-
ease severity, as shown in Figure 1 (r = 0.465, p <
0.01).
RELATIONSHIP BETWEEN URINARY EDN CON-
CENTRATION IN ATOPIC DERMATITIS AND VAS
ASSESSMENTS
As Figures 2, 4, 5 show, urinary EDN concentrations
significantly correlated with each VAS score for itch-
ing, skin condition and overall skin symptoms, which
Urinary EDN Concentrations in Atopic Dermatitis
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Fig. 3 Relationships between urinary EDN concentrations 
and VAS score for skin dryness in patients with atopic 
dermatitis. There was no significant corelation between uri
nary EDN concentrations and the VAS score (r＝0.200).
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Fig. 4 Significant relationships between urinary EDN con
centrations and VAS score for skin condition in patients with 
atopic dermatitis. The corelation between urinary EDN con
centrations and the VAS score was r＝0.532, p＜0.01.
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Fig. 5 Significant relationships between urinary EDN con
centrations and VAS score for overal skin symptoms, which 
was the sum of three individual skin aspects (itching, skin 
dryness, skin condition), in patients with atopic dermatitis. 
The corelation between urinary EDN concentrations and 
the VAS score was r＝0.445, p＜0.05.
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Fig. 6 Significant relationships between urinary EDN con
centrations and total VAS score which was the sum of the 
scores of nine items in patients with atopic dermatitis. The 
corelation between urinary EDN concentrations and the 
VAS score was r＝0.446, p＜0.05.
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was the sum of three individual skin aspects (itching,
skin dryness, skin condition) (r = 0.601, p < 0.001, r =
0.532, p < 0.01 and r = 0.445, p < 0.05, respectively).
However, there was no significant correlation be-
tween EDN concentration in urine and VAS score for
skin dryness (r = 0.200) (Fig. 3). There was a signifi-
cant correlation between urinary EDN concentrations
and the total VAS score, which was the sum of the
scores of the nine items (r = 0.446, p < 0.05) (Fig. 6).
However, there was no significant correlation be-
tween urinary EDN concentration and individual VAS
scores such as those for general physical condition,
fatigue, mental stress, sleep, excessive eating or
drinking, and excessive work or study.
NUMBER OF EOSINOPHILS IN PERIPHERAL
BLOOD FROM PATIENTS WITH ATOPIC DER-
MATITIS AND URINARY EDN CONCENTRA-
TIONS IN THE PATIENTS
As Figure 7 shows, no significant relationships were
observed between urinary concentrations of EDN
and the number of eosinophils in peripheral blood
from the patients with atopic dermatitis (r = −0.208).
DISCUSSION
It has been suggested that measurements of
eosinophil-derived proteins in serum, especially as-
sessment of serum ECP, may be used to reflect the
inflammatory activities of eosinophils in allergic dis-
eases. However, ECP is a very sticky and extremely
Goto T et al.
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Fig. 7 Relationships between urinary EDN concentrations 
and the number of peripheral blood eosinophils in patients 
with atopic dermatitis. There was no significant corelation 
between urinary EDN concentrations and the number (r＝
－0.208).
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charged protein,13 and the clinical usefulness of ECP
has been questioned because of problems in sample
processing and the great variability of measured val-
ues.2
EDN, also called EPX, is the basic eosinophil gran-
ule protein which can be accurately measured only in
urine,3 and it has been reported that urinary EDN
may be a valid alternative to the measurements of
eosinophil proteins in the serum.4 Recent studies
have indicated the usefulness of measuring the con-
centrations of urinary EPX in monitoring childhood
bronchial asthma,14,15 and atopic dermatitis in chil-
dren and adults.16-18 However, we are aware of no re-
port indicating the relationship between urinary EDN
concentrations from patients with allergic diseases
and the disease severity, or of a linear analogue scale
questionnaire for evaluating patient-reported clinical
activity.
We reported an efficient ELISA method specifically
for measuring human blood and urinary EDN.5 In ad-
dition, we showed that the method may be useful for
indicating the possible roles of eosinophils in ongoing
asthma6 and allergic diseases.7 We have expanded
these studies and, in this paper, urinary concentra-
tions of EDN in patients with atopic dermatitis
showed a significant positive correlation with the se-
verity of the disease, supporting the previous data
that urinary EPX is an in vitro parameter of inflamma-
tion in atopic dermatitis.18
Some scoring systems for evaluating clinical itch
have been described in the literature.19 The Euro-
pean Task Force on Atopic Dermatitis has developed
a composite severity index based on a broad consen-
sus by dermatologists. The resulting SCORAD in-
dex20 (scoring of atopic dermatitis) combines objec-
tive symptoms (extent, intensity) and subjective crite-
ria (daytime pruritus and sleep loss). It has been ex-
tensively tested in trials, although it seems compli-
cated for a routine clinical setting. Sprikkelman et
al.21 showed poor agreement between the SCORAD
index and other scoring systems in assessing the se-
verity of atopic dermatitis. Darsow et al.22 presented
the English version of a multidimensional itch ques-
tionnaire (Eppendorf Itch Questionnaire) which was
developed in Germany in a cooperative effort be-
tween dermatologists and neurophysiologists as a
modified analogon to the McGill index. Pucci et al.23
have reported that infants and young children with
atopic dermatitis have distinctive intensity items of
the SCORAD index that probably depend on a dis-
tinctive immunopathogenesis. However, they also re-
ported that the SCORAD index still remains the gold
standard for grading the severity of atopic dermatitis
in everyday practice and clinical trials.
Recently, simple questionnaires using a linear ana-
logue scale have been developed to measure and
quantify disturbances in the health-related quality of
life of patients with allergic diseases such as atopic
dermatitis24 and bronchial asthma.25 It has been dem-
onstrated that a simple VAS score of patient assess-
ment of disease severity showed the highest and
most significant correlations with most of the health-
related quality of life in patients with atopic dermati-
tis,24 and a linear analogue scale questionnaire was
useful for assessing health-related quality of life in
elderly patients.26 In this study, we used a 10 cm
VAS consisting of nine items with “none” on the left
side of the scale and “severe” on the right. As a re-
sult, urinary EDN concentrations in patients with
atopic dermatitis were found to correlate with VAS
scores for itching, skin condition, overall skin symp-
toms and total VAS score, indicating that measure-
ments of urinary EDN concentrations are useful for
monitoring disease activity in atopic dermatitis.
Patients with atopic dermatitis commonly have dry
skin, particularly on the extensor surfaces of the ex-
tremities, and impairment of the water permeability
barrier function in the skin has been suggested.27
However, it has been shown that atopic dry skin re-
vealed normal barrier structures, and dry skin disor-
ders were not always accompanied by an impairment
of the water permeability barrier.28 In fact, it has been
demonstrated that an insufficiency of ceramides in
the stratum corneum was an etiologic factor in atopic
dry and barrier-disrupted skin,29 and sphingomyelin
metabolism was altered in skin affected by atopic der-
matitis.30 Interestingly, in the present study, urinary
EDN concentrations in patients with atopic dermatitis
did not correlate with VAS scores for skin dryness, in-
dicating less involvement of eosinophilic inflamma-
tion in the formation of atopic dry skin. Further stud-
ies are required.
Urinary EDN concentrations in patients with atopic
dermatitis did not correlate with the number of pe-
ripheral blood eosinophils, and these data support the
Urinary EDN Concentrations in Atopic Dermatitis
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findings of our previous report.7 It has been reported
that urinary EPX may reflect disease activity, and
measurements of urinary EPX may reflect the inflam-
matory activity of eosinophils in atopic dermatitis in
children and adults.16-18 Considering our results,
counting the eosinophils in peripheral blood may not
be useful in assessing the disease activity of atopic
dermatitis.
In this study, urine was collected from each patient
who came on a first visit to our hospital, and EDN
concentrations in urine were measured. However, the
preliminary study from our laboratory7 has already
shown that EDN concentrations in the urine from pa-
tients with atopic dermatitis were higher when their
skin symptoms were active than when they were not.
So, the question remains as to whether serial urinary
EDN concentrations in patients with atopic dermatitis
correlate with VAS scores in parallel with their clini-
cal symptoms such as itching and skin condition.
Very recently, Fujisawa et al.31 reported that serum
measurement of thymus and activation-regulated
chemokineCCL17 represented accurately the dis-
ease activity of atopic dermatitis. Further studies are
required to ascertain whether urinary EDN concen-
tration can serve as an adequate clinical marker of
atopic dermatitis.
In conclusion, our results in this paper demon-
strate that measurement of the urinary EDN concen-
tration is useful for monitoring disease activity in
atopic dermatitis.
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